APA-Zitierstil (7. Ausg.)

Haag, G. M., Zörnig, I., Hassel, J. C., Halama, N., Dick, J., Lang, N., . . . Jäger, D. (2018). Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. European journal of cancer, 90, . https://doi.org/10.1016/j.ejca.2017.12.001

Chicago-Zitierstil (17. Ausg.)

Haag, Georg Martin, et al. "Phase II Trial of Ipilimumab in Melanoma Patients with Preexisting Humoural Immune Response to NY-ESO-1." European Journal of Cancer 90 (2018). https://doi.org/10.1016/j.ejca.2017.12.001.

MLA-Zitierstil (9. Ausg.)

Haag, Georg Martin, et al. "Phase II Trial of Ipilimumab in Melanoma Patients with Preexisting Humoural Immune Response to NY-ESO-1." European Journal of Cancer, vol. 90, 2018, https://doi.org/10.1016/j.ejca.2017.12.001.